Peripheral Immune Response Patterns Under Vital Qi-Strengthening and Toxin-Eliminating Therapy and Their Value in Assessing Vital Qi Deficiency in Lung Cancer Metastasis: A Group-Based Trajectory Modeling
10.3971/j.issn.1000-8578.2026.26.0073
- VernacularTitle:基于群组轨迹模型分析扶正蠲毒法干预下外周免疫应答模式及其对肺癌转移“正虚”的评估价值
- Author:
Fan XU
1
;
Jianhui TIAN
1
;
Yuan YAO
1
;
Zhenyang CHENG
1
;
Yanhong WANG
1
;
Bin LUO
2
;
Jialiang YAO
2
;
Wang YAO
2
;
Xinyi LU
2
;
Yuchen BAO
2
;
Xiaoyu YANG
1
;
Youjun LIU
1
;
Yiyang ZHOU
2
;
Jianchun WU
2
;
Minghua LI
2
;
Wenfei SHI
2
;
Yajing CUI
2
;
Qingzhong LIU
3
;
Yan LI
2
;
Yun YANG
2
Author Information
1. Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China;Institute of Oncology, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
2. Clinical Oncology Center, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
3. Department of Clinical Laboratory, Shanghai Municipal Hospital of Traditional Chinese Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China.
- Publication Type:CLINICALRESEARCH
- Keywords:
Tumor metastatic state;
Vital qi-strengthening and toxin-eliminating therapy (Fuzheng Juandu);
Lung cancer metastasis;
Peripheral immune response pattern;
Trajectory analysis
- From:
Cancer Research on Prevention and Treatment
2026;53(9):711-717
- CountryChina
- Language:Chinese
-
Abstract:
Objective On the basis of the theory of the tumor metastatic state, this work aims to explore the metastasis trajectories and peripheral immune response patterns in patients with non-small cell lung cancer (NSCLC) receiving vital qi-strengthening and toxin-eliminating therapy (Fuzheng Juandu) and reveal the value of peripheral immunity in assessing vital qi deficiency during metastasis. Methods A retrospective study design was adopted. Patients with NSCLC admitted from January 1, 2018, to October 31, 2025 were enrolled. Data on metastasis status and peripheral immune indices were collected at the follow-up time points of one, two, three, and five years. Group-based trajectory modeling was used to fit metastasis trajectories, and the independent predictors of trajectory grouping were analyzed through multifactor and multiclassification logistic regression. Results A total of 184 patients with NSCLC were included, and three different groups of metastasis trajectories were identified, namely, the low-risk stable (46.74%, n=86), low-risk rising (13.59%, n=25), and high-risk stable (39.67%, n=73) groups. Univariate analysis revealed substantial differences in peripheral immune indices among the three trajectory groups. Multivariate analysis showed that TNM stage, absolute neutrophil count, lymphocyte count, absolute monocyte count, platelet volume, SAA:CRP ratio, and NLR were independent predictors of the low-risk rising group, whereas TNM stage, absolute monocyte count, basophil count, SII, and NLR were independent predictors of the high-risk stable group. Conclusion Under Fuzheng Juandu therapy, patients with NSCLC exhibit three distinct metastasis trajectories, each corresponding to a specific peripheral immune response pattern. Elucidating these peripheral immune response patterns may facilitate the objective quantification of the degree of vital qi deficiency, prediction of future metastasis risk, and providing an important reference for the individualized clinical implementation of Fuzheng Juandu therapy.
